Development of the small-molecule antiviral ST-246® as a smallpox therapeutic

Future Virology

Volumn 6, Issue 5, 2011, Pages 653-671

  Grosenbach, Douglas W ^a   Jordan, Robert ^a   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

Author keywords

animal rule; antiviral; CBRN medical countermeasures; FDA approval; monkeypox; smallpox; strategic national stockpile; zoonotic orthopoxvirus

Indexed keywords

CIDOFOVIR; IMIQUIMOD; METISAZONE; TECOVIRIMAT;

AREA UNDER THE CURVE; ARENAVIRUS; ATAXIA; BOVINE VIRAL DIARRHEA; COWPOX VIRUS; CYTOMEGALOVIRUS; DISEASE TRANSMISSION; DNA REPLICATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; EPIDEMIC; ERADICATION THERAPY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HERPES SIMPLEX VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; KIDNEY INJURY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RIFT VALLEY FEVER BUNYAVIRUS; ROTAVIRUS; SINGLE DRUG DOSE; SMALLPOX; SMALLPOX VIRUS; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; VACCINIA; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALIA; ORTHOPOXVIRUS; VARIOLA VIRUS;

EID: 79957582537     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.27     Document Type: Review

References (75)

1. Franz DR, Jahrling PB, Friedlander AM et al.: Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278(5), 399-411 (1997). (Pubitemid 27327459)
2. Nicas M, Hubbard A, Jones R, Reingold R: The infectious dose of variola (smallpox) virus. Applied Biosafety 9(3), 118-127 (2004).
3. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID: Smallpox and its Eradication. WHO, Switzerland (1988).
4. Gellman B: 4 Nations Thought to Possess Smallpox. The Washington Post, 5 November 2002.
5. Strikas RA, Neff LJ, Rotz L et al.: US Civilian Smallpox Preparedness and Response Program, 2003. Clin. Infect. Dis. 46(Suppl. 3), S157-S167 (2008). (Pubitemid 351590127)
6. Henderson DA, Inglesby TV, Bartlett JG et al.: Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281(22), 2127-2137 (1999). (Pubitemid 29264692)
7. Weiss MM, Weiss PD, Mathisen G, Guze P: Rethinking smallpox. Clin. Infect. Dis. 39(11), 1668-1673 (2004).
8. Enserink M: Infectious diseases. Smallpox vaccination campaign in the doldrums. Science 300(5621), 880-881 (2003). (Pubitemid 36548840)
9. Earl PL, Moss B, Wyatt LS, Carroll MW: Generation of recombinant vaccinia viruses. Curr. Protoc. Mol. Biol. Chapter 16, Unit 16.17 (2001).
10. Earl Pl, Cooper N, Wyatt S, Moss B, Carroll MW: Preparation of cell cultures and vaccinia virus stocks. Curr. Protoc. Mol. Biol. Chapter 16, Unit 16.16 (2001).
11. Andrew ME, Coupar BE: Biological effects of recombinant vaccinia virus-expressed interleukin 4. Cytokine 4(4), 281-286 (1992).
12. Massung RF, Liu LI, Qi J et al.: Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 201(2), 215-240 (1994). (Pubitemid 24187268)
13. Henderson DA: The looming threat of bioterrorism. Science 283(5406), 1279-1282 (1999).
14. Bossi P, Tegnell A, Baka A et al.: Bichat guidelines for the clinical management of smallpox and bioterrorism-related smallpox. Euro Surveill. 9(12), E7-E8 (2004).
15. Kretzschmar M, Van Den Hof S, Wallinga J, Van Wijngaarden J: Ring vaccination and smallpox control. Emerg. Infect. Dis. 10(5), 832-841 (2004). (Pubitemid 38552750)
16. Kaplan EH: Preventing second-generation infections in a smallpox bioterror attack. Epidemiology 15(3), 264-270 (2004). (Pubitemid 40416944)
17. Legrand J, Viboud C, Boelle PY, Valleron AJ, Flahault A: Modelling responses to a smallpox epidemic taking into account uncertainty. Epidemiol. Infect. 132(1), 19-25 (2004). (Pubitemid 38240068)
18. Kaplan EH, Craft DL, Wein LM: Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl Acad. Sci. USA 99(16), 10935-10940 (2002).
19. Meltzer MI, Damon I, Leduc JW, Millar JD: Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis. 7(6), 959-969 (2001). (Pubitemid 33115774)
20. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA: Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37(2), 251-271 (2003). (Pubitemid 36930357)
21. Kemper AR, Davis MM, Freed GL: Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5(2), 84-90 (2002).
22. Lane JM, Ruben FL, Neff JM, Millar JD: Complications of smallpox vaccination, 1968: results of ten statewide surveys. J. Infect. Dis. 122(4), 303-309 (1970).
23. Kretzschmar M, Wallinga J, Teunis P, Xing S, Mikolajczyk R: Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. 3(8), E272 (2006).
24. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG: The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341(1), 91-101 (2005). (Pubitemid 41356718)
25. Earl PL, Americo JL, Wyatt LS et al.: Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428(6979), 182-185 (2004). (Pubitemid 38374314)
26. Empig C, Kenner JR, Perret-Gentil M et al.: Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 3686-3694 (2006).
27. Mccurdy LH, Larkin BD, Martin JE, Graham BS: Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38(12), 1749-1753 (2004). (Pubitemid 38781668)
28. Morikawa S, Sakiyama T, Hasegawa H et al.: An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J. Virol. 79(18), 11873-11891 (2005). (Pubitemid 41279305)
29. Saijo M, Ami Y, Suzaki Y et al.: LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol. 80(11), 5179-5188 (2006).
30. Stittelaar KJ, Van Amerongen G, Kondova I et al.: Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79(12), 7845-7851 (2005). (Pubitemid 40756819)
31. Vollmar J, Arndtz N, Eckl KM et al.: Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24(12), 2065-2070 (2005). (Pubitemid 43255148)
32. Kidokoro M, Tashiro M, Shida H: Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl Acad. Sci. USA 102(11), 4152-4157 (2005).
33. Artenstein AW, Johnson C, Marbury TC et al.: A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 23(25), 3301-3309 (2005). (Pubitemid 40523124)
34. Monath TP, Caldwell JR, Mundt W et al.: ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2), S31-S44 (2004). (Pubitemid 39445966)
35. Weltzin R, Liu J, Pugachev KV et al.: Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9(9), 1125-1130 (2003). (Pubitemid 37173695)
36. Yang G, Pevear DC, Davies MH et al.: An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79(20), 13139-13149 (2005). (Pubitemid 41433232)
37. Duraffour S, Snoeck R, De Vos R et al.: Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 12(8), 1205-1216 (2007).
38. Chen Y, Honeychurch KM, Yang G et al.: Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 6, 44 (2009).
39. Smith GL, Vanderplasschen A, Law M: The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83(Pt 12), 2915-2931 (2002). (Pubitemid 36054337)
40. Jahrling PB, Hensley LE, Martinez MJ et al.: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl Acad. Sci. USA 101(42), 15196-15200 (2004). (Pubitemid 39391741)
41. Payne LG: Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50(1), 89-100 (1980). (Pubitemid 11211415)
42. Blasco R, Moss B: Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 65(11), 5910-5920 (1991).
43. Gurt I, Abdalrhman I, Katz E: Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antiviral Res. 69(3), 158-164 (2005). (Pubitemid 43247336)
44. Mcintosh AA, Smith GL: Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J. Virol. 70(1), 272-281 (1996). (Pubitemid 126508795)
45. Wolffe EJ, Isaacs SN, Moss B: Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J. Virol. 67(8), 4732-4741 (1993). (Pubitemid 23215953)
46. Jordan R, Leeds JM, Tyavanagimatt S, Hruby D: Development of ST-246® for treatment of poxvirus infections. Viruses 2, 2409-2435 (2010).
47. Berhanu A, King DS, Mosier S et al.: ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 53(12), 4999-5009 (2009).
48. Grosenbach DW, Berhanu A, King DS et al.: Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl Acad. Sci. USA 107(2), 838-843 (2010).
49. Quenelle DC, Buller RM, Parker S et al.: Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51(2), 689-695 (2007). (Pubitemid 46185291)
50. Sbrana E, Jordan R, Hruby De et al.: Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76(4), 768-773 (2007). (Pubitemid 351627722)
51. Nalca A, Hatkin JM, Garza NL et al.: Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 79(2), 121-127 (2008).
52. Huggins J, Goff A, Hensley L et al.: Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53(6), 2620-2625 (2009).
53. Jordan R, Goff A, Frimm A et al.: ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53(5), 1817-1822 (2009).
54. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L: The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81(12), 1581-1600 (2001). (Pubitemid 33144422)
55. Edghill-Smith Y, Golding H, Manischewitz J et al.: Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11(7), 740-747 (2005). (Pubitemid 41021206)
56. Fogg CN, Americo JL, Lustig S et al.: Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25(15), 2787-2799 (2007). (Pubitemid 46412575)
57. Heraud JM, Edghill-Smith Y, Ayala V et al.: Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177(4), 2552-2564 (2006). (Pubitemid 44201014)
58. Hooper JW, Thompson E, Wilhelmsen C et al.: Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78(9), 4433-4443 (2004). (Pubitemid 38501063)
59. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP: Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26(4), 581-588 (2008).
60. Nigam P, Earl PL, Americo JL et al.: DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 366(1), 73-83 (2007). (Pubitemid 47314398)
61. Stittelaar KJ, Neyts J, Naesens L et al.: Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439(7077), 745-748 (2006). (Pubitemid 43237623)
62. CDC: Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb. Mortal. Wkly Rep. 58(19), 532-536 (2009).
63. Vora S, Damon I, Fulginiti V et al.: Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46(10), 1555-1561 (2008). (Pubitemid 351706737)
64. Jordan R, Tien D, Bolken TC et al.: Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52(5), 1721-1727 (2008). (Pubitemid 351614665)
65. Rimoin AW, Mulembakani PM, Johnston SC et al.: Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl Acad. Sci. USA 107(37), 16262-16267 (2010).
66. Vorou RM, Papavassiliou VG, Pierroutsakos IN: Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 21(2), 153-156 (2008). (Pubitemid 351641518)
67. De Souza Trindade G, Drumond BP, Guedes MI et al.: Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals. J. Clin. Microbiol. 45(4), 1370-1372 (2007). (Pubitemid 46626521)
68. Hutin YJ, Williams RJ, Malfait P et al.: Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg. Infect. Dis. 7(3), 434-438 (2001).
69. Parker S, Nuara A, Buller RM, Schultz DA: Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2, 17-34 (2007). (Pubitemid 46766996)
70. Kile JC, Fleischauer AT, Beard B et al.: Transmission of monkeypox among persons exposed to infected prairie dogs in Indiana in 2003. Arch. Pediatr. Adolesc. Med. 159(11), 1022-1025 (2005). (Pubitemid 41633359)
71. Shearer JD, Siemann L, Gerkovich M, House RV: Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob. Agents Chemother. 49(7), 2634-2641 (2005). (Pubitemid 40917572)
72. Magee WC, Hostetler KY, Evans DH: Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49(8), 3153-3162 (2005). (Pubitemid 41060553)
73. Quenelle DC, Prichard MN, Keith KA et al.: Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51(11), 4118-4124 (2007). (Pubitemid 350057813)
74. Grosenbach DW, Jordan R, King DS et al.: Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 26(7), 933-946 (2008).
75. Berhanu A, King DS, Mosier S et al.: Impact of ST-246® on ACAM2000 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 29(2), 289-303 (2010).